Viatris Remains a Key Player in the Generic Drug Industry.

From Nov. 17, Viatris will be the surviving company formed by the combination of leading generic maker Mylan and Upjohn, Pfizer's generics business. The new entity will continue to focus on the prior Mylan strategy focused on generic and biosimilar drugs and will also manufacture key mature branded drugs from Pfizer, including Lipitor (cholesterol), Lyrica (pain), Norvasc (high blood pressure), Celebrex (arthritis), in addition to numerous other generic medications. Mylan shareholders will have a minority share, about 43%, interest in the new combination, and Pfizer shareholders will own the majority balance.